Mr. Gabriel Fahel reports

CYBIN TO HOST CONFERENCE CALL AND WEBCAST TO PROVIDE PROGRAM UPDATE FOR CYB003

Cybin Inc. will host a conference call and webcast at 8:30 a.m. ET on Wednesday, March 13, 2024.

The company will provide a program update on CYB003, its proprietary deuterated psilocybin analogue, in development for the adjunctive treatment of MDD, including four-month durability results from the company's phase 2 trial.

Conference call and webcast details

Date:  Wednesday, March 13, 2024

Time:  8:30 a.m. ET

Dial-in:  800-267-6316 (United States toll-free) or 203-518-9783 (international)

Conference ID:  CYBN0313

Webcast:  Register for the webcast.

The archived webcast will also be available on the company's investor relations website on the events and presentations page.

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analogue, for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.